Survival adjusting for crossover: Phase 3 study of ibrutinib vs. chlorambucil in older patients with untreated chronic lymphocytic leukemia/small lymphocytic lymphoma

TY - JOUR

T1 - Survival adjusting for crossover

T2 - Phase 3 study of ibrutinib vs. chlorambucil in older patients with untreated chronic lymphocytic leukemia/small lymphocytic lymphoma

AU - Coutre, Steven

AU - Tedeschi, Alessandra

AU - Robak, Tadeusz

AU - Barr, Paul M.

AU - Owen, Carolyn

AU - Bairey, Osnat

AU - Burger, Jan

AU - Zhou, Cathy

AU - Styles, Lori

AU - James, Danelle F.

AU - Kipps, Thomas J.

N1 - Funding Information: 1Stanford University School of Medicine, CA, USA;2ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy;3Medical University of Lodz, Poland;4Wilmot Cancer Institute, University of Rochester Cancer Center, NY, USA;5Tom Baker Cancer Centre, University of Calgary, Canada;6Rabin Medical Center, Beilinson Campus, Petah Tikvah, Israel;7Sackler Faculty of Medicine, University, Tel Aviv, Israel;8University of Texas MD Anderson Cancer Center, Houston, TX, USA;8Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA, USA and 10University of California, San Diego, Moores Cancer Center, La Jolla, CA, USA Correspondence: [email protected] doi:10.3324/haematol.2017.175380 Acknowledgments: the authors would like to thank the patients who participated in the study, their supporters, and the investigators and clinical research staff from the study centers. This manuscript was developed with editorial support from Stacey Rose, PhD, and funded by Pharmacyclics LLC, an AbbVie Company.

PY - 2018/6/3

Y1 - 2018/6/3

UR - https://www.scopus.com/pages/publications/85048052554

U2 - 10.3324/haematol.2017.175380

DO - 10.3324/haematol.2017.175380

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.letter???

C2 - 29170253

AN - SCOPUS:85048052554

SN - 0390-6078

VL - 103

SP - e249-e251

JO - Haematologica

JF - Haematologica

IS - 6

ER -